Lilly preps for ph. 2 launch after Verve gene editor cuts cholesterol on par with PCSK9 inhibitors - Fierce Biotech

Lilly preps for ph. 2 launch after Verve gene editor cuts cholesterol on par with PCSK9 inhibitors Fierce Biotech One-and-Done Heart Disease Prevention? Scientists Show It May Be Possible. The New York Times A single dose of Lilly's PCSK9 base editor, VERVE-102, reduced PCSK9 by up to 88% and LDL-C by up to 62%, with durable effects supporting its potential as a one-time treatment for hypercholesterolemia investor.lilly.com Eli Lilly says Verve’s gene editor lowers cholesterol levels in early st